Cytarabine Export Market Intelligence: India's 175 Suppliers Shipping to 110 Countries — TransData Nexus 2026

Q: Who are the top cytarabine exporters from India?

The top cytarabine exporters from India are: 1. INTAS PHARMACEUTICALS LIMITED — $5.1M (47.6% market share); 2. FRESENIUS KABI ONCOLOGY LIMITED — $1.8M (16.9% market share); 3. NAPROD LIFE SCIENCES PRIVATE LIMITED — $557.0K (5.2% market share); 4. ZYDUS HOSPIRA ONCOLOGY PRIVATE LIMITED — $498.8K (4.6% market share); 5. CELON LABORATORIES PRIVATE LIMITED — $313.6K (2.9% market share). Together they account for 77.2% of India's total cytarabine export value.

Q: What is the total export value of cytarabine from India?

The total export value of cytarabine from India is $10.7M USD, recorded across 1,825 shipment transactions from 175 active exporters to 110 destination countries. The average shipment value is $5.9K.

Q: Which countries import cytarabine from India?

India exports cytarabine to 110 countries worldwide. The top importing countries are: NETHERLANDS (13.5% share, $1.4M), BRAZIL (12.5% share, $1.3M), UNITED KINGDOM (5.0% share, $542.4K), AUSTRALIA (4.8% share, $517.7K), SOUTH AFRICA (4.6% share, $489.1K). These five markets account for 40.3% of total export value.

Q: What is the HS code for cytarabine exports from India?

The primary HS code for cytarabine exports from India is 30049049. This 8-digit classification falls under Chapter 30 (pharmaceutical products) of the Harmonized System and is used by Indian Customs (DGFT) for tracking and reporting pharmaceutical trade flows.

Q: What is the average price of cytarabine exports from India?

The average unit price for cytarabine exports from India is $5.99 USD per unit, with prices ranging from $0.05 to $1266.33 depending on formulation, packaging, and order volume. The total market is valued at $10.7M across 1,825 shipments.

Q: Which ports handle cytarabine exports from India?

The primary ports for cytarabine exports from India are SAHAR AIR CARGO ACC (INBOM4) (13.6% of shipments), SAHAR AIR (13.3% of shipments), DELHI AIR (8.7% of shipments), AHEMDABAD AIR ACC (INAMD4) (7.9% of shipments), DELHI AIR CARGO ACC (INDEL4) (7.9% of shipments). These ports have dedicated pharmaceutical cargo infrastructure ensuring cold-chain and regulatory compliance during transit.

Q: Why is India a leading exporter of cytarabine?

India is one of the world's leading exporters of cytarabine due to its large base of 175 WHO-GMP and US FDA approved manufacturers, significantly lower production costs compared to Western markets, well-established API (Active Pharmaceutical Ingredient) supply chains, and strong government support for pharmaceutical exports through the Pharmaceuticals Export Promotion Council (Pharmexcil). India exports cytarabine to 110 countries, demonstrating 56% global market coverage.

Q: What certifications do Indian cytarabine exporters need?

Indian cytarabine exporters typically require WHO-GMP (Good Manufacturing Practice) certification for most regulated markets, US FDA approval for exports to the United States, EU GMP certification for European markets, and country-specific regulatory approvals for markets in Africa, Asia, and Latin America. Additional certifications may include ISO 9001, Schedule M compliance under Indian drug laws, and Free Sale Certificates issued by the Central Drugs Standard Control Organization (CDSCO).

Q: How many buyers import cytarabine from India?

There are 381 registered buyers importing cytarabine from India, spread across 110 countries. The repeat buyer rate is 56.7%, indicating strong long-term trade relationships and consistent product quality.

Q: What is the market share of the top cytarabine supplier from India?

INTAS PHARMACEUTICALS LIMITED is the leading cytarabine exporter from India with a market share of 47.6% and total export value of $5.1M across 693 shipments. The top 5 suppliers together control 77.2% of total export value.

Suresh Sormare

Cytarabine

India Pharmaceutical Trade Intelligence

$10.7M175 Suppliers110 CountriesHS 30049049

ExportsIndia → NETHERLANDS13.5%India → BRAZIL12.5%

ImportsAUSTRALIA → India$4.5M BULGARIA → India$34.8K

#1 Supplier: INTAS PHARMACEUTICALS #1 Buyer: ALLOGA FRANCE

Cytarabine Export Analysis | India Pharmaceutical Trade Intelligence | TransData Nexus

How India Exports Cytarabine to the World

Between 2022 and 2026, India exported $10.7M worth of cytarabine across 1,825 verified shipments to 110 countries — covering 56% of world markets in the Advanced Oncology segment. The largest destination is NETHERLANDS (13.5%). INTAS PHARMACEUTICALS LIMITED leads with a 47.6% share. All figures are drawn from Indian Customs (DGFT) shipping bill records spanning four years of trade activity.

Source: Indian Customs (DGFT)·Published March 2026·Updated March 2026·

Cytarabine export data from India — top exporters, importing countries, pricing and trade statistics compiled by TransData Nexus — Cytarabine export data snapshot — $10.7M · 175 exporters · 110 countriesTransData Nexus · Indian Customs Data

Top Cytarabine Exporters from India

175 active exporters · Ranked by export value

View all 175 →

Top Cytarabine Exporters from India — Ranked by Export Value
#	Supplier Name	Export Value (USD)	Shipments	Countries	Market Share
1	INTAS PHARMACEUTICALS LIMITED	$5.1M	693	14	47.6%
2	FRESENIUS KABI ONCOLOGY LIMITED

Top Countries Importing Cytarabine from India

110 destination markets · Ranked by import value

All 110 countries →

Top Countries Importing Cytarabine from India — Ranked by Import Value
#	Country	Import Value (USD)	Market Share
1	NETHERLANDS	$1.4M	13.5%
2	BRAZIL	$1.3M	12.5%
3	UNITED KINGDOM	$542.4K	5.0%
4	AUSTRALIA	$517.7K	4.8%
5	SOUTH AFRICA	$489.1K	4.6%
6	PHILIPPINES	$475.0K	4.4%
7	SPAIN	$464.2K	4.3%
8	THAILAND	$408.0K	3.8%
9	COLOMBIA	$406.6K	3.8%
10	ITALY	$381.9K	3.6%

NETHERLANDS is India's largest cytarabine export destination, absorbing 13.5% of total exports worth $1.4M. The top 5 importing countries — NETHERLANDS, BRAZIL, UNITED KINGDOM, AUSTRALIA, SOUTH AFRICA — together account for 40.3% of India's total cytarabine export value. The remaining 105 destination countries collectively receive the other 59.7%, indicating a well-diversified global distribution network spanning all major continents.

Who Supplies Cytarabine to India?

5 origin countries · Total import value: $4.5M

India imports cytarabine from 5 countries with a combined import value of $4.5M. The largest supplier is AUSTRALIA ($4.5M, 15 shipments), followed by BULGARIA and UNITED STATES. All values are from Indian Customs (DGFT) import records.

Countries Supplying Cytarabine to India — Ranked by Import Value
#	Origin Country	Import Value (USD)	Shipments	Share
1	AUSTRALIA	$4.5M	15	99.2%
2	BULGARIA	$34.8K	1	0.8%
3	UNITED STATES	$1.8K	4	0.0%
4	SWITZERLAND	$1.5K	1	0.0%
5	THAILAND	$72	6	0.0%

AUSTRALIA is the largest supplier of cytarabine to India, accounting for 99.2% of total import value. The top 5 origin countries — AUSTRALIA, BULGARIA, UNITED STATES, SWITZERLAND, THAILAND — together supply 100.0% of India's cytarabine imports. Click any country to see detailed supplier and buyer data for that import corridor.

Regulatory Landscape — Cytarabine

Product-specific regulatory status across FDA, EMA, WHO, and CDSCO · As of March 2026

1FDA & US Market Regulatory Status

In the United States, cytarabine is approved for the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia, and chronic myelocytic leukemia. The FDA's Orange Book lists multiple approved Abbreviated New Drug Applications (ANDAs) for cytarabine, indicating a competitive generic market. The absence of current import alerts or significant regulatory actions suggests a stable regulatory environment for cytarabine imports into the U.S. Given the substantial number of Indian exporters, this stability is crucial for maintaining consistent supply chains.

2EU & UK Regulatory Framework

Within the European Union, cytarabine is subject to the European Medicines Agency's (EMA) centralized marketing authorization process. A notable development occurred in July 2018 when the marketing authorization for DepoCyte, a liposomal formulation of cytarabine, was withdrawn at the request of the marketing authorization holder, Pacira Ltd, due to commercial reasons. This withdrawal underscores the dynamic nature of the regulatory landscape. Manufacturers exporting to the EU and UK must adhere to Good Manufacturing Practice (GMP) standards as outlined by the EMA and the UK's Medicines and Healthcare products Regulatory Agency (MHRA).

3WHO Essential Medicines & Global Standards

Cytarabine is included in the 24th edition of the WHO Model List of Essential Medicines, published in September 2025, highlighting its critical role in treating priority health conditions globally. This inclusion emphasizes the necessity for its availability and affordability worldwide. Compliance with international pharmacopoeia standards, such as the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), is essential to ensure the quality and efficacy of cytarabine formulations.

4India Regulatory Classification

In India, cytarabine is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential medicines; however, as of March 2026, cytarabine is not listed under the Drug Price Control Order (DPCO), allowing market-driven pricing. For exports, the Directorate General of Foreign Trade (DGFT) mandates a No Objection Certificate (NOC) to ensure compliance with national and international regulations.

5Patent & Exclusivity Status

The primary patents for cytarabine have expired, facilitating the production and export of generic versions by multiple manufacturers. This has led to increased competition and more affordable pricing in the global market.

6Recent Industry Developments

In May 2025, the WHO Expert Committee on Selection and Use of Essential Medicines convened to update the Model List of Essential Medicines, reaffirming cytarabine's inclusion due to its continued relevance in treating hematological malignancies. This underscores the ongoing global recognition of cytarabine's importance in oncology.

In September 2025, the WHO published the 24th edition of the Model List of Essential Medicines, which includes cytarabine, highlighting its critical role in treating priority health conditions globally. (who.int)

In January 2026, the WHO released a fact sheet on essential medicines, emphasizing the importance of medicines like cytarabine in treating priority health-care needs and their inclusion in the WHO Model List of Essential Medicines. (who.int)

These developments reflect the dynamic nature of the pharmaceutical industry and the importance of staying informed about regulatory changes and market trends to ensure compliance and strategic positioning in the global market.

TransData Nexus Research · FDA Orange Book, EMA, WHO Model List, CDSCO/NPPAUpdated Mar 2026

Get Complete Export Intelligence Report

300+ pages · Supplier profiles · Buyer analysis · Price benchmarks · Every shipment record

Free

Global Price Benchmark — Cytarabine

Retail & reference prices across 9 markets vs. India FOB export price of $5.99/unit

Global Price Benchmark for Cytarabine across major pharmaceutical markets
Market	Price (USD/unit)	Currency	Reference
United States	Data not available	USD	Pricing information for Cytarabine 100 mg vials is not publicly disclosed by the FDA.
United Kingdom	Data not available	GBP	The NHS Drug Tariff does not list a standard price for Cytarabine 100 mg vials.
Germany	Data not available	EUR	The German Federal Joint Committee (G-BA) does not provide specific pricing for Cytarabine 100 mg vials.
Australia	Data not available

Supply Chain Risk Assessment — Cytarabine

API sourcing, concentration risk, storage requirements, and current alerts

HIGH RISK

1API Sourcing & Raw Material Dependency

Cytarabine, a critical chemotherapeutic agent, is predominantly manufactured in India. However, the production of its Active Pharmaceutical Ingredient (API) heavily relies on Key Starting Materials (KSMs) sourced from China. This dependency is significant, as China controls approximately 70–80% of the global KSM supply and 60–70% of the global intermediate supply, making it a dominant player in the pharmaceutical raw material market.

The reliance on Chinese KSMs introduces substantial risks to the supply chain. Any disruptions in China's production capabilities—be it due to environmental regulations, geopolitical tensions, or other factors—can lead to shortages and increased costs for APIs. For instance, in July 2018, shutdowns of Chinese chemical plants due to environmental concerns led to significant supply constraints and price hikes for Indian pharmaceutical manufacturers.

2Supplier Concentration & Single-Source Risk

Our proprietary trade data indicates that the top five Indian exporters account for 77.2% of Cytarabine exports, with INTAS PHARMACEUTICALS LIMITED alone contributing 47.6%. This high concentration among a few suppliers poses a significant risk; any operational disruptions within these key companies could severely impact global Cytarabine availability.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme, aiming to bolster domestic API and KSM production. Notably, in October 2024, two greenfield plants were inaugurated under this scheme to manufacture critical molecules like Penicillin G and Clavulanic Acid, marking a step towards reducing import dependence. However, the effectiveness of the PLI scheme in diversifying Cytarabine's supplier base remains to be seen.

Access Complete Cytarabine Trade Intelligence

Shipment-level records, verified supplier contacts, buyer histories, and pricing analytics for all 1,825 transactions across 110 markets.

Request Demo View Pricing

Frequently Asked Questions — Cytarabine Exports from India

Data-backed answers sourced from Indian Customs shipping bill records

Who are the top cytarabine exporters from India?

The leading cytarabine exporters from India are INTAS PHARMACEUTICALS LIMITED, FRESENIUS KABI ONCOLOGY LIMITED, NAPROD LIFE SCIENCES PRIVATE LIMITED, and 11 others. INTAS PHARMACEUTICALS LIMITED leads with 47.6% market share ($5.1M). The top 5 suppliers together control 77.2% of total export value.

What is the total export value of cytarabine from India?

The total export value of cytarabine from India is $10.7M, recorded across 1,825 shipments from 175 active exporters to 110 countries. The average shipment value is $5.9K.

Which countries import cytarabine from India?

India exports cytarabine to 110 countries. The top importing countries are NETHERLANDS (13.5%), BRAZIL (12.5%), UNITED KINGDOM (5.0%), AUSTRALIA (4.8%), SOUTH AFRICA (4.6%), which together account for 40.3% of total export value.

What is the HS code for cytarabine exports from India?

The primary HS code for cytarabine exports from India is 30049049. This 8-digit classification falls under Chapter 30 (pharmaceutical products) of the Harmonized System and is used by Indian Customs (DGFT) to track and report pharmaceutical export flows.

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Cytarabine

Cytarabine

Top Cytarabine Exporters from India

Top Countries Importing Cytarabine from India

Who Supplies Cytarabine to India?

Quick Facts

Related Advanced Oncology

Related Analysis

Need Details?

Regulatory Landscape — Cytarabine

1FDA & US Market Regulatory Status

2EU & UK Regulatory Framework

3WHO Essential Medicines & Global Standards

4India Regulatory Classification

5Patent & Exclusivity Status

6Recent Industry Developments

Global Price Benchmark — Cytarabine

Supply Chain Risk Assessment — Cytarabine

1API Sourcing & Raw Material Dependency

2Supplier Concentration & Single-Source Risk

Access Complete Cytarabine Trade Intelligence

Frequently Asked Questions — Cytarabine Exports from India

Who are the top cytarabine exporters from India?

What is the total export value of cytarabine from India?

Which countries import cytarabine from India?

What is the HS code for cytarabine exports from India?

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

India Cost Advantage

3Geopolitical & Shipping Disruptions

4Risk Mitigation Recommendations

What is the average price of cytarabine exports from India?

Which ports handle cytarabine exports from India?

Why is India a leading exporter of cytarabine?

What certifications do Indian cytarabine exporters need?

How many buyers import cytarabine from India?

What is the market share of the top cytarabine exporter from India?

Analysis Methodology